Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management

V. Peřina, R. Salzman, J. Treglerová

. 2024 ; 103 (5) : 277-281. [pub] 20211021

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014222

Background: Antiresorptive drugs are widely used to reduce bone mineral loss in patients with osteoporosis and to prevent skeletal-related events in patients with metastatic cancers and multiple myeloma (MM). Both the bisphosphonates (BP) and denosumab typically used in this indication were shown to be effective and relatively safe. Obviously, this medication could have some adverse effects; one of them is osteonecrosis of the external auditory canal. Only sporadic cases of external auditory canal osteonecrosis have been published yet. Here, we provide a case of denosumab-related osteonecrosis of the external auditory canal successfully treated surgically in the early stage of the disease. Case report: A 68-year-old patient with breast cancer underwent comprehensive oncological treatment, including denosumab administration. She was diagnosed with osteonecroses in the jaw and ear canal. The necrotic bones in both regions were resected with primary wound closure. Both affected sites healed well with no signs of necrosis recurrence. Conclusions: Osteonecrosis of the external auditory canal is a rare but probably underdiagnosed complication of antiresorptive medication. It has a negative impact on patient quality of life if left untreated. Early surgical treatment appears to be effective. The authors highlight several similarities with medication-related osteonecrosis of the jaw. Therefore, an analogous disease staging and treatment rationale is suggested.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014222
003      
CZ-PrNML
005      
20240905133821.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/01455613211053389 $2 doi
035    __
$a (PubMed)34672841
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Peřina, Vojtěch $u Department of Oral and Maxillofacial Surgery, Masaryk University-Faculty of Medicine and University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000191658323
245    10
$a Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management / $c V. Peřina, R. Salzman, J. Treglerová
520    9_
$a Background: Antiresorptive drugs are widely used to reduce bone mineral loss in patients with osteoporosis and to prevent skeletal-related events in patients with metastatic cancers and multiple myeloma (MM). Both the bisphosphonates (BP) and denosumab typically used in this indication were shown to be effective and relatively safe. Obviously, this medication could have some adverse effects; one of them is osteonecrosis of the external auditory canal. Only sporadic cases of external auditory canal osteonecrosis have been published yet. Here, we provide a case of denosumab-related osteonecrosis of the external auditory canal successfully treated surgically in the early stage of the disease. Case report: A 68-year-old patient with breast cancer underwent comprehensive oncological treatment, including denosumab administration. She was diagnosed with osteonecroses in the jaw and ear canal. The necrotic bones in both regions were resected with primary wound closure. Both affected sites healed well with no signs of necrosis recurrence. Conclusions: Osteonecrosis of the external auditory canal is a rare but probably underdiagnosed complication of antiresorptive medication. It has a negative impact on patient quality of life if left untreated. Early surgical treatment appears to be effective. The authors highlight several similarities with medication-related osteonecrosis of the jaw. Therefore, an analogous disease staging and treatment rationale is suggested.
650    _2
$a lidé $7 D006801
650    12
$a denosumab $x škodlivé účinky $x terapeutické užití $7 D000069448
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    12
$a zvukovod $x chirurgie $x patologie $7 D004424
650    12
$a inhibitory kostní resorpce $x škodlivé účinky $7 D050071
650    12
$a osteonekróza $x chemicky indukované $x chirurgie $7 D010020
650    12
$a nádory prsu $x farmakoterapie $x chirurgie $7 D001943
650    _2
$a nemoci ucha $x chemicky indukované $x chirurgie $7 D004427
650    _2
$a bisfosfonátová osteonekróza čelistí $x chirurgie $x etiologie $7 D059266
655    _2
$a časopisecké články $7 D016428
655    _2
$a kazuistiky $7 D002363
700    1_
$a Salzman, Richard $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Treglerová, Jana $u Department of Oral and Maxillofacial Surgery, Masaryk University-Faculty of Medicine and University Hospital Brno, Brno, Czech Republic
773    0_
$w MED00005690 $t Ear, nose, & throat journal $x 1942-7522 $g Roč. 103, č. 5 (2024), s. 277-281
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34672841 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133815 $b ABA008
999    __
$a ok $b bmc $g 2143799 $s 1226088
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 103 $c 5 $d 277-281 $e 20211021 $i 1942-7522 $m Ear, nose, & throat journal $n Ear Nose Throat J $x MED00005690
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...